Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Effects of Alzheimer's disease transgenes on neurochemical expression in the mouse brain determined by ¹H MRS in vitro.

Forster DM, James MF, Williams SR.

NMR Biomed. 2012 Jan;25(1):52-8. doi: 10.1002/nbm.1712. Epub 2011 Aug 26.

PMID:
22241671
3.

Treatment effects in a transgenic mouse model of Alzheimer's disease: a magnetic resonance spectroscopy study after passive immunization.

Marjańska M, Weigand SD, Preboske G, Wengenack TM, Chamberlain R, Curran GL, Poduslo JF, Garwood M, Kobayashi D, Lin JC, Jack CR Jr.

Neuroscience. 2014 Feb 14;259:94-100. doi: 10.1016/j.neuroscience.2013.11.052. Epub 2013 Dec 4.

4.

Altered neurochemical profile in the McGill-R-Thy1-APP rat model of Alzheimer's disease: a longitudinal in vivo 1 H MRS study.

Nilsen LH, Melø TM, Saether O, Witter MP, Sonnewald U.

J Neurochem. 2012 Nov;123(4):532-41. doi: 10.1111/jnc.12003. Epub 2012 Oct 1.

5.

Age-related changes in brain metabolites and cognitive function in APP/PS1 transgenic mice.

Chen SQ, Cai Q, Shen YY, Wang PJ, Teng GJ, Zhang W, Zang FC.

Behav Brain Res. 2012 Nov 1;235(1):1-6. doi: 10.1016/j.bbr.2012.07.016. Epub 2012 Jul 22.

PMID:
22828014
6.

Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study.

Huang W, Alexander GE, Chang L, Shetty HU, Krasuski JS, Rapoport SI, Schapiro MB.

Neurology. 2001 Aug 28;57(4):626-32.

PMID:
11524470
7.

In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.

Frederick BD, Lyoo IK, Satlin A, Ahn KH, Kim MJ, Yurgelun-Todd DA, Cohen BM, Renshaw PF.

Prog Neuropsychopharmacol Biol Psychiatry. 2004 Dec;28(8):1313-22.

PMID:
15588758
8.

Proton and phosphorus magnetic resonance spectroscopy of a mouse model of Alzheimer's disease.

Mlynárik V, Cacquevel M, Sun-Reimer L, Janssens S, Cudalbu C, Lei H, Schneider BL, Aebischer P, Gruetter R.

J Alzheimers Dis. 2012;31 Suppl 3:S87-99.

PMID:
22451319
9.

Metabolic brain mapping in Alzheimer's disease using proton magnetic resonance spectroscopy.

Lazeyras F, Charles HC, Tupler LA, Erickson R, Boyko OB, Krishnan KR.

Psychiatry Res. 1998 May 20;82(2):95-106.

PMID:
9754452
10.

The effects of aging, housing and ibuprofen treatment on brain neurochemistry in a triple transgene Alzheimer's disease mouse model using magnetic resonance spectroscopy and imaging.

Choi JK, Carreras I, Aytan N, Jenkins-Sahlin E, Dedeoglu A, Jenkins BG.

Brain Res. 2014 Nov 24;1590:85-96. doi: 10.1016/j.brainres.2014.09.067. Epub 2014 Oct 6.

11.

Proton magnetic resonance spectroscopy reveals similar white matter biochemical changes in patients with chronic hypertension and early Alzheimer's disease.

Catani M, Mecocci P, Tarducci R, Howard R, Pelliccioli GP, Mariani E, Metastasio A, Benedetti C, Senin U, Cherubini A.

J Am Geriatr Soc. 2002 Oct;50(10):1707-10.

PMID:
12366626
12.

Magnetic Resonance Spectroscopy in Alzheimer's Disease: Systematic Review and Meta-Analysis.

Wang H, Tan L, Wang HF, Liu Y, Yin RH, Wang WY, Chang XL, Jiang T, Yu JT.

J Alzheimers Dis. 2015;46(4):1049-70. doi: 10.3233/JAD-143225. Review.

PMID:
26402632
13.

Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey.

García Santos JM, Gavrila D, Antúnez C, Tormo MJ, Salmerón D, Carles R, Jiménez Veiga J, Parrilla G, Torres del Río S, Fortuna L, Navarro C.

Dement Geriatr Cogn Disord. 2008;26(1):15-25. doi: 10.1159/000140624. Epub 2008 Jun 20.

PMID:
18566544
14.

Proton magnetic resonance spectroscopy as a probe into the pathophysiology of autism spectrum disorders (ASD): a review.

Baruth JM, Wall CA, Patterson MC, Port JD.

Autism Res. 2013 Apr;6(2):119-33. doi: 10.1002/aur.1273. Epub 2013 Feb 21. Review.

PMID:
23436782
15.

Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy.

Pilatus U, Lais C, Rochmont Adu M, Kratzsch T, Frölich L, Maurer K, Zanella FE, Lanfermann H, Pantel J.

Psychiatry Res. 2009 Jul 15;173(1):1-7. doi: 10.1016/j.pscychresns.2008.07.015. Epub 2009 May 9.

PMID:
19427767
16.

1H NMR metabolomic signatures in five brain regions of the AβPPswe Tg2576 mouse model of Alzheimer's disease at four ages.

Lalande J, Halley H, Balayssac S, Gilard V, Déjean S, Martino R, Francés B, Lassalle JM, Malet-Martino M.

J Alzheimers Dis. 2014;39(1):121-43. doi: 10.3233/JAD-130023.

PMID:
24145382
17.

Elevated brain scyllo-inositol concentrations in patients with Alzheimer's disease.

Griffith HR, den Hollander JA, Stewart CC, Evanochko WT, Buchthal SD, Harrell LE, Zamrini EY, Brockington JC, Marson DC.

NMR Biomed. 2007 Dec;20(8):709-16.

PMID:
17295394
18.

Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy.

Marjanska M, Curran GL, Wengenack TM, Henry PG, Bliss RL, Poduslo JF, Jack CR Jr, Ugurbil K, Garwood M.

Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11906-10. Epub 2005 Aug 9.

19.

Proton MRS in mild cognitive impairment.

Kantarci K.

J Magn Reson Imaging. 2013 Apr;37(4):770-7. doi: 10.1002/jmri.23800. Review.

20.

(1)H-magnetic resonance spectroscopy ((1)H-MRS) in methamphetamine dependence and methamphetamine induced psychosis.

Howells FM, Uhlmann A, Temmingh H, Sinclair H, Meintjes E, Wilson D, Stein DJ.

Schizophr Res. 2014 Mar;153(1-3):122-8. doi: 10.1016/j.schres.2014.01.029. Epub 2014 Feb 12.

PMID:
24529366

Supplemental Content

Support Center